Category: Miscellaneous


In Silico Genesis presented our Alzheimer’s strategy to the One Nucleus CNS Leadership Seminar Series held in London, on the 11th of Feb. 2013.

isg_on2

This seminar will look at:

• The Prime Minister’s Dementia Challenge
• Pharmacotherapy for Alzheimer’s disease – progress and prospects
• The emerging scientific advances that may enable greater success in the future

Agenda:

10.30 – Registration

11.00 – Welcome from the Chair
Janet Knowles, Partner, Eversheds

11.10 – The Prime Minister’s Dementia Challenge
Mark Treherne, CEO, Life Sciences Investment Organisation, UKTI

11.30 – What are the prospects of slowing the progression of Alzheimer’s disease?
Prof Alan Palmer, Director MS Therapeutics

12.00 – What insights do biomarkers provide into the recent Phase III failures?
Andrea Les, Senior Imaging Scientist, IXICO

12.20 – Q&A with the speakers

12.45 – Networking Lunch

13.45 – Introduction from the Chair
Philip Oliver

13.45 Is there a future for the amyloid theory in treating Alzheimer’s disease?
Eric Karran, Alzheimer’s Research UK

14.05 Targeting Tau hyperphosporylation in AD
Ian Pike, COO, Proteome Sciences

14.25 – Genetic basis of Alzheimer disease susceptibility
Prof. Julie Williams, Cardiff University School of Medicine

14.45 – FGL Peptides as neuroprotectives in AD
Steve Rees, COO, ENKAM Pharmaceuticals A/S

15.05 – Translational genomic medicine and companion diagnostic development
Kimberley Treherne
(then, Williams), In Silico Genesis

15.25 – Closing Remarks from one Nucleus
Tony Jones, Director of Business Development, One Nucleus

15.30 – Networking drinks

16.30 – Close

Shown above can be found at http://onenucleus.com/onenucleus-events?id=692.

VF_ISGIn Silico Genesis Ltd presented at Venturefest Oxford 2013, at the request of Oxfordshire Bioscience Network (OBN) to represent the regional biocluster at OBN BioElevator session. This took place in Lecture Theatre 5, SAID Business School of Oxford University on Tuesday, 18th of June, 2013. The session was chaired by the chairman of the Oxfordshire Bioscience Network and attended by the CEO of OBN, Dr. Jon Rees.

In the runner-up to BioTrinity/Venturefest Oxford 2013, In Silico Genesis Limited was also approached by the OBN, about supporting a governmental initiative for the field of Life Sciences in the United Kingdom. In brief, the OBN gave me an opportunity to work with the Office of Life Sciences (OLS). Enclosed is a letter IMG_0001, forwarded to me by the OBN, from the Treasury of Her Majesty’s government. I am thankful to SAID Business School (http://www.sbs.ox.ac.uk/) of the University of Oxford for having taught me and guided me in this entrepreneurial journey,  during my biochemistry/bioinformatics work undertaken at Oxford. Thank you Oxford for everything you taught me. From Kimberley Treherne, xxx

Find us @insilicogenesis at https://twitter.com.

ISG will produce abundant cash flow in order to return:

we commit ourselves to give 1/10 of whatever profits back, sharing the overflowing and exceeding goodness of God with others on this planet; contact@trehernefoundation.org.